Mitigare

Mitigare^® Capsules Now Preferred by …

Mitigare® Colchicine Capsules are now preferred by these commercial formularies.

Mitigare^® Colchicine Capsules Now Preferred!

Effective July 1, 2019

Mitigare^® (Colchicine) 0.6 mg Capsules are now Preferred on Blue Cross Blue Shield (BCBS) commercial formularies in 14 states.

Be sure to have it in stock for your customers!

SEE PLAN DETAILS

Stock up on Mitigare^®

Don’t forget to replenish your inventory of Mitigare^® (Colchicine) 0.6 mg Capsules.

Covered by over 80% of insurance plans.*

Mitigare (Colchicine) 0.6 mg Capsules

Product	NDC#	Bottle
Mitigare^® 0.6 mg Capsules	59467-318-30	30 ct
Mitigare^® 0.6 mg Capsules	59467-318-01	100 ct
Mitigare^® 0.6 mg Capsules	59467-318-10	1,000 ct

*Managed Markets Insight & Technology, LLC database and formulatory status as of May 1, 2019.

PHARMACIST INFORMATION

Additional Savings For Gout Flare Prevention May Be Available

Eligible patients pay as little as $0* first 30 days and $5 refills

With the Mitigare^® True Blue Savings Card, eligible patients can receive Mitigare^® (Colchicine) 0.6 mg Capsules for as little as $0 for the first 30 days and get $5 refills.*

Can be used on Generic Colchicine Capsules or Mitigare^® Capsules.

SEE HOW IT WORKS

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. Please see complete Terms & Conditions.

Important Safety Information

Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare^®.
Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare^®.
The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare^® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied. Mitigare^® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

WW00821

Privacy Policy